Board summary
Key figures
46,702
Registered population
64.5% aged 18–64
17.1%
Aged 65+
ICB 19.9% · England 17.9%
14.9%
Ethnic minority (non-White)
5.6% Asian · England 9.6%
17.5%
In IMD quintile 1
ICB 17.1% · England 21.0%
~7,615
Core20 residents (est.)
Resident basis; registered basis ~8,559 · see page 3
5,782
Hypertension register
+8.75% in 3 yrs · England +5.60%
479
SMI register
22.7% of Canterbury's
555
COPD register
Reviews -2.53% in 3 yrs
Forecast to 2030
7,320
Hypertension patients, 2030
+1,538 on today
63.3%
QRISK ≥20% on statins, 2030
+4.01pp over 3 yrs
5.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail England after three-year drop.
Annual asthma reviews fell 10.0% over 3 years (England +4.4%) to 53.1% (England 65.7%), a 1,153 unreviewed scale indicator that may reflect recall gaps.
High-risk lipid therapy and prescribing rates lag England.
Lipid therapy reaches 54.3% for QRISK ≥ 20% (England 63.6%) and 63.5% in CKD (England 70.3%), with 1,270 adult lipid items/1,000 (England 4,100).
Population, age and ethnicity
Working-age patients comprise 64.5% of the list alongside 733 catchment care home beds
Canterbury South PCN serves 46,702 registered patients across three practices. Working-age adults (18–64) comprise 64.5% (Canterbury 62.9%, NHS Kent and Medway ICB 59.5%, England 62.7%), while patients aged 65+ represent 17.1% (7,982 patients; Canterbury 18.4%, ICB 19.9%, England 17.9%). Census usual residents in associated areas—not registered patients—are 85.1% White (England 81.1%), 5.6% Asian (England 9.6%) and 3.9% Black (England 4.2%). Recorded learning disability prevalence is 0.4% (Canterbury 0.6%, England 0.6%), with 0.2% at University Medical Centre and 0.4% at Canterbury Medical Practice.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Canterbury local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Canterbury LA) | 1,577 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.6% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.0% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Canterbury LA) | 682 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Canterbury LA) | 18.2 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 averages 17.5% across the PCN but reaches 34.2% at New Dover Road Surgery
The PCN Core20 share is 17.5%, below Canterbury (19.3%), above NHS Kent and Medway ICB (17.1%) and below England (21.0%). Practice shares span 20.8 pp: New Dover Road Surgery holds the highest concentration at 34.2% (3,526 estimated patients), while Canterbury Medical Practice accounts for an estimated 3,372 patients (14.1%). An estimated 7,615 residents live in deciles 1 and 2, though weighted practice shares (18.3%) differ by 0.84 percentage points. Outreach should balance concentrated deprivation at New Dover Road Surgery with high overall volume at Canterbury Medical Practice.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
479
SMI register
0.97% recorded prevalence
182
Learning disability register
0.37% recorded prevalence
28
Care homes, 733 beds
In the PCN catchment
9.3%
Provide unpaid care
Canterbury, Census 2021
The PCN records 479 severe mental illness patients (1.0%, matching England 1.0%) and 182 on the learning disability register (0.4%; England 0.6%), alongside 28 catchment care homes (733 beds). Local authority snapshot data records 29 rough sleepers in autumn 2025, while applying the borough unpaid-care rate yields an estimated ceiling of 4,343 carers. Trailing learning disability prevalence could reflect coding differences that an audit would test.
Severe mental illness: physical health checks
Recorded severe mental illness check elements trail England: blood pressure checks reached 76.7% (England 83.4%) and body mass index 76.2% (England 82.1%). This is consistent with recall gaps that comprehensive physical health check reviews would clarify.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,782
Hypertension register
+8.75%
Register growth, 3 yrs
Canterbury +3.48% · England +5.60%
+3.52pp
BP control, under 80
≤140/90 · +1.64pp aged 80+
+1,538
More patients by 2030
Forecast 7,320 (13.86%)
Hypertension case-finding and control
Recorded hypertension prevalence is 11.7% (5,782 patients), below Canterbury (15.6%), NHS Kent and Medway ICB (16.2%) and England (15.2%). Recent blood pressure recording reaches 86.4% (England 90.0%), and treatment to target is 66.8% (England 70.3%). Among patients aged under 80, control to <= 140/90 mmHg is 63.5% (England 67.8%), spanning from 68.0% at New Dover Road Surgery to 62.1% at Canterbury Medical Practice and 60.6% at University Medical Centre. Control for patients aged 80 and over is 77.3% (England 81.2%). Observation periods are unconfirmed, and crude prevalence differences do not establish undiagnosed disease. Trailing national benchmarks across age groups could reflect recall or titration differences that a clinical audit would test.
Lipids and statins
Lipid-lowering therapy reaches 54.3% for QRISK ≥ 20% (England 63.6%) and 63.5% in CKD (England 70.3%). Statin therapy in diabetes with CVD is 79.0% (England 84.4%), after falling 1.4 pp over three years (England +0.8 pp). These gaps against England could reflect review or prescribing recall patterns that a clinical audit would clarify.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 48,413 | £2.00 | £1.90 | £1.86 | £96,826 |
| Cardiovascular (all), 2025 | 71,455 | £4.01 | £3.57 | £3.33 | £286,535 |
For lipid-regulating drugs in 2026, the PCN prescribed 48,413 items at £2.00 per item (Canterbury £2.23, NHS Kent and Medway ICB £1.90, England £1.86). The PCN spends £6,778 more than at England's unit cost across these items. This unit-cost indicator does not establish inefficiency, though local formulary choices could be reviewed to verify mix.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−9.99%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.85%
Asthma prevalence, PCN 3-yr % change
Asthma annual reviews fell 10.0% over three years (England +4.4%) to 53.1%, trailing England (65.7%), NHS Kent and Medway ICB (60.4%) and Canterbury (56.4%), leaving about 1,200 register patients unreviewed (1,153 on a register of 2,457). Youth asthma prescribing reached 976 items per 1,000 aged 5-19 against 1,488 in England. In contrast, COPD reviews reached 76.4%, matching England (76.4%) on a register of 555 patients (1.1% prevalence). This divergence could reflect differing recall processes that an audit of disease registers would test.
Cancer register and children's immunisation
Cancer register prevalence is 3.8% (1,886 patients), matching England (3.8%). In Q1 2025/26, 6-in-1 coverage at 24 months reached 97.5% (England 92.2%), above the 95.0% target. At age 5, second-dose MMR is 91.8% (4.7 pp below first-dose 96.5%, cohort 85) and 4-in-1 booster is 89.4%, below the 95.0% target by 5.6 pp. This drop could reflect pre-school recall attrition that practice-level audit would test.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, 55.6% of cancers with a known stage in NHS Kent and Medway ICB were diagnosed at stage 1 or 2 (England 55.3%), showing a distance of -19.4 pp to the 75.0% national ambition by 2028 (a gap of 1,627 early-stage cases across the ICB). Staging data reflects system diagnosis rather than PCN performance, and coverage is incomplete: only 63.6% of registered cancers had a recorded stage (England 67.0%). Canterbury South PCN cancer prevalence is 3.8% (1,886 patients), rising +15.6% over three years (England +9.0%). Cervical screening (ages 25-49) reached 66.9% (ICB 69.9%), ranging from 59.8% at University Medical Centre to 70.2% at Canterbury Medical Practice.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, East Kent Hospitals University NHS Foundation Trust achieved 70.0% on the 62-day cancer standard against the 85.0% standard (ICB 75.9%, England 71.2%; East Sussex Healthcare NHS Trust 67.0%, Medway NHS Foundation Trust 81.6%). On the 28-day faster diagnosis standard, East Kent reached 71.3% against the 75.0% standard (ICB 76.8%, England 79.3%). For diagnostic waits in July 2026, 48.4% of patients at East Kent waited 6+ weeks across all tests (East Sussex Healthcare NHS Trust 5.3%, Medway NHS Foundation Trust 14.2%, England 23.1%). Provider waits reflect acute system pressures rather than PCN performance.
| Pathways within standard (%) | East Kent | Medway | East Sussex Healthcare | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 71.28 | 77.77 | 84.20 | 76.78 | 79.32 |
| 31-day treatment (96%) | 96.67 | 99.62 | 98.19 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 70.01 | 81.64 | 67.04 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Kent | Medway | East Sussex Healthcare | England |
|---|---|---|---|---|
| MRI | 47.58 | 0.68 | 6.48 | 21.40 |
| CT | 37.45 | 0.00 | 0.48 | 9.92 |
| Echocardiography | 14.17 | 36.62 | 21.94 | 28.48 |
| Colonoscopy | 9.58 | 1.88 | 0.74 | 30.83 |
| Gastroscopy | 22.16 | 3.32 | 0.31 | 29.02 |
| All 15 DM01 tests | 48.38 | 14.20 | 5.27 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In June 2026, provisional experimental statistics recorded 265,905 community care activities for residents of Kent and 297,595 across NHS Kent and Medway Integrated Care Board. Contacts with adults aged 65 and over represented 65.8% of contacts among borough residents. These experimental figures reflect submitting providers for local authority residents and the wider system, rather than an exclusive PCN patient cohort.
Practice variation and patient experience
QOF vaccination achievement spans 69.0 pp across practices despite uniform 100.0% clinical achievement
In 2025/26, QOF clinical achievement reached 100.0% at Canterbury Medical Practice, New Dover Road Surgery and University Medical Centre (England 97.1%). However, vaccination achievement spanned 69.0 pp, from 25.0% at New Dover Road Surgery to 94.0% at University Medical Centre (Canterbury Medical Practice 58.5%; England 55.2%). Personalised care adjustments ranged from 10.7% to 15.9% (England 10.0%), consistent with operational variation.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| New Dover Road | 92 | 34.2 | 58.9% | 63.7% | 86.5% |
| University | 125 | 13.3 | 71.5% | 74.7% | 79.7% |
| Canterbury | 122 | 14.1 | 37.3% | 70.3% | 74.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 tracked trajectories trail England despite strong heart failure review gains
Across 25 tracked measures, 15 three-year trajectories trail England. Major relative lags include asthma reviews, falling 10.0% (Canterbury +2.0%, NHS Kent and Medway ICB +1.1%, England +4.4%), and learning disability prevalence, falling 3.0% (England +5.4%). Mental health checks also lagged national gains for alcohol recording (+0.8 pp vs +5.4 pp) and blood pressure (+1.0 pp vs +4.4 pp). Conversely, heart failure reviews rose 46.1% (England +8.7%) and cervical screening rose 6.4% (England -1.0%). Divergent trends could reflect uneven recall or coding across pathways, which a targeted review would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
Learning disability register
COPD reviews
Alcohol record (psychosis)
Breast screening (53-70)
Heart failure reviews
Cervical screening
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Canterbury | Asset | PCN | Canterbury |
|---|---|---|---|---|---|
| Care homes (catchment) | 28 (733 beds) | n/a | Schools (catchment) | 85 | n/a |
| Children's centres | 3 | 8 | Places of worship | 84 | 103 |
| Libraries | 2 | 2 | Food banks (VCS) | 1 | no data |
| Day centres (VCS) | 5 | 4 | Children and young people (VCS) | n/a | 1 |
| Carers support groups (VCS) | 3 | 4 | Primary schools (LA maintained) | 17 | 19 |
| Primary academies | 10 | 13 | Special schools | 2 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma annual reviews are 53.1% (Canterbury 56.4%, NHS Kent and Medway ICB 60.4%, England 65.7%), falling 10.0% over 2023 to 2025 (England +4.4%), with 1,153 unreviewed on a 2,457 register. For discussion, the PCN could run a single-template asthma recall and inhaler check across practices with flexible slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school booster and LD register audit
In Q1 2025/26, age-5 MMR2 is 91.8% vs 96.5% MMR1 (4.7 pp difference; New Dover Road Surgery 9.5 pp) and 4-in-1 is 89.4% (below 95.0% by 5.6 pp). LD prevalence is 0.4% (182 patients; England 0.6%), falling 3.0% (England +5.4%). Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Option 3
CVD lipid, BP and SMI recall
Lipid therapy is 54.3% for QRISK ≥ 20% (England 63.6%), 63.5% in CKD (England 70.3%) and 79.0% in diabetes with CVD (-1.4 pp). Under-80 BP control is 63.5% (England 67.8%; University Medical Centre 60.6%) and SMI BP checks are 76.7% (England 83.4%). Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register audit (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation call-recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Pre-school booster and LD register audit (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN & Practice |
| Option 3 · CVD lipid, BP and SMI recall (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 · MHIS · From Harm to Hope | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
